Navigation Links
Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
Date:8/25/2010

LAS VEGAS, Aug. 25 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that CEO Matt Schissler was interviewed recently by Tom Allinder of InBoundMarketingPR.

During the course of the interview, Mr. Schissler discussed contents of recent financially related news releases – retirement of the $1.1 million debt obligation with JMJ Financial on 5 August, 2010 and details from the 18 August, 2010 news release detailing the company's quarterly earnings. Mr. Schissler also discusses recent news that a federal judge temporarily blocked the Obama administration Monday from using federal dollars to fund expanded human embryonic stem cell research and how the news impacts Cord Blood America. The interview is accessible at http://inboundmarketingpr.com/clients/cord-blood-america/bid/45397/Interview-with-Matt-Schissler-CEO-of-Cord-Blood-America

About Cord Blood AmericaCord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.CONTACT:Paul KnopickE & E Communications949/707-5365pknopick@eandecommunications.com
'/>"/>

SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cord Blood America Reports 12% Increase in 2010 Second Quarter Revenue
2. China Cord Blood Corporation Announces Cancellation of Nine Million Management Incentive Warrants
3. China Cord Blood Corporation Joins Russell Global Index
4. Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
5. Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
6. Scientists Give the Go-Ahead for Private Storage of Stem Cells From Umbilical Cord Blood
7. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
8. FirstAidWarehouse.co.uk Examines High Blood Pressure, or Hypertension, and Blood Pressure Monitors
9. New Promega Maxwell 16 LEV Blood DNA Kit Surpasses Concentration Standards in Less Time
10. Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study
11. China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):